“In normal haematopoiesis, stem cells are homogenous, whereas in clonal haematopoiesis stem cells are genetically diverse due to acquired somatic mutations,” Dr Margarete Fabre (University of Cambridge, UK) explained. “We conducted a study to unravel the transition from normal to clonal haematopoiesis and map the dynamics of clonal haematopoiesis.”
Dr Fabre and colleagues assessed 13 years of blood samples, collected from an elderly population (n=385; mean age at baseline 69.3 years). Deep targeted sequencing was used to detect mutant clones. The results displayed that the mean clone size and number of mutations increased with age, with constant growth rates in >90% of the detected clones. DNMT3A, TET2, and spliced mutant clones were the most common drivers of these mutations. Non-genetic factors accounted for approximately 5% of the clonal growth, proportionally impacting slow driver genes more substantially. Furthermore, mutations associated with faster clonal growth were also associated with an increased risk of acute myeloid leukaemia, independent of clone size.
Next, retrograde extrapolation was performed to assess clonal expansion longitudinally. The results showed that some genetic mutations drive fast clonal expansions early in life and then slow down, such as DNMT3A mutations, whereas other drivers initiate expansion at an older age at a fast growth rate, such as splicing mutations. Still other mutations occur at all ages and demonstrate relatively stable growth, such as TET2-mutant clones (see Figure).
Figure: Different patterns of lifelong clonal behaviour [1]

Whole-genome sequencing of 1,731 single cell-derived colonies confirmed the inferences that were made from the longitudinal data. However, reconstruction of haematopoietic phylogenies showed that many clones lacked recognisable drivers and that these driverless expansions displayed similar growth rates.
In conclusion, the current findings improve the understanding of lifelong clonal behaviour by showing that clonal haematopoiesis is driven by different gene mutations that demonstrate separate patterns of longitudinal clonal behaviour.
- Fabre M, et al. The Longitudinal Dynamics and Natural History of Clonal Hematopoiesis. LBA-2, ASH 2021 Annual Meeting, 11–14 December.
Copyright ©2022 Medicom Medical Publishers
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma Next Article
Reduced risk of Alzheimer’s disease in CHIP carriers »
« Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma Next Article
Reduced risk of Alzheimer’s disease in CHIP carriers »
Table of Contents: ASH 2021
Featured articles
Acute Lymphoblastic Leukaemia
New Interfant protocol includes blinatumomab for KMT2A-r ALL
Persistent disparities in ALL health outcomes
EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL
UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL
Acute Myeloid Leukaemia
AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML
Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients
Promising frontline triplet regimen for TP53-mutated AML
Encouraging results of novel triplet combination for AML
Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML
Improved risk stratification in MDS via gene-based scoring system
Chronic Leukaemia
CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL
SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naĂŻve CLL/SLL
Investigational therapies superior to standard-of-care in double-exposed CLL
Multiple Myeloma
GRIFFIN: Sustained responses of daratumumab plus RVd in MM
MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM
iStopMM: Smouldering MM highly prevalent in general population
Mechanisms of D-KRd treatment failure in MM identified
TRIMM-2: Favourable results of talquetamab plus daratumumab for MM
Lymphoma
Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma
Axi-cel improved event-free survival in R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in DLBCL
POLARIX: Novel regimen superior to R-CHOP in DLBCL
Novel non-invasive biomarker ctDNA shows value in CNS lymphoma
Myeloproliferative Neoplasms
Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms
JAK2V617F variant allele frequency prognostic of venous events in polycythaemia vera
Immune Thrombocytopenia
Promising results of tacrolimus plus dexamethasone for ITP
Sustained remission after TPO-RA discontinuation in chronic ITP
Haemophilia
Fitusiran meets primary endpoint in ATLAS-A/B trial
ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors
rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors
Clonal Haematopoiesis
Reduced risk of Alzheimer’s disease in CHIP carriers
Lifelong patterns of clonal haematopoiesis revealed
Related Articles
February 4, 2022
Reduced risk of Alzheimer’s disease in CHIP carriers
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy